Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,446.11 +64.76 (+0.77%) Bitcoin USD
63,253.39 +1,875.44 (+3.06%) CMC Crypto 200
1,306.85 -51.16 (-3.77%)
Celltrion, Inc. (068270.KS)
| Previous close | 189,700.00 |
| Open | 193,300.00 |
| Bid | 192,800.00 x 0 |
| Ask | 192,900.00 x 0 |
| Day's range | 192,000.00 - 196,900.00 |
| 52-week range | 131,000.00 - 241,000.00 |
| Volume | |
| Avg. volume | 646,144 |
| Market cap | 39.902T |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 500.00 (0.26%) |
| Ex-dividend date | 27 Dec 2023 |
| 1y target est | N/A |
- PR Newswire
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be priced as WAC list price at an 85% discount to the current WAC list price of HUMIRA. Adalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC lis
- PR Newswire
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA-approved subcutaneous infliximab ZYMFENTRA™
Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives. Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA™ (inf
- PR Newswire
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
